INTERVIEW: Dr. Reddy’s COO On Derma Build Up, Biologics Norms
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's Laboratories (DRL) appears to be building on plans for its differentiated dermatology and neurology formulations in the US after gains on the approvals front.
You may also be interested in...
Early Strides for Takeda’s Qdenga In Brazil, India Deal Adds New Dimension
Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s public vaccination program and outlines the contours, including pricing aspects, of the deal with Biological E for the dengue vaccine. The US IND application for the jab is still open.
Obituary: Ranjit Shahani, Ex-Novartis India Chief Who ‘Traveled Light’
Industry veteran and mentor to many, Ranjit Shahani steered Novartis India with seeming calm through a rocky phase when the Glivec patent case ruling didn't go the Swiss multinational's way - perhaps not unusual for someone who had seen the ebbs and flows of life closely when his parents moved to India as refugees from Pakistan.
BMS CDTO Meyers On Gen AI Use Cases, Long-Range Planning Models
Bristol Myers Squibb’s EVP and chief digital and technology officer, Greg Meyers, tells Scrip how the company is using data, technology and artificial intelligence to speed up the clinical research process. An AI engine that leverages real-world data to improve trial diversity and promising generative AI uses cases are some of the key topics discussed.